Front. Neurosci. Frontiers in Neuroscience Front. Neurosci. 1662-453X Frontiers Media S.A. 10.3389/fnins.2025.1667076 Neuroscience Correction Correction: Protective effects of Hif2 inhibitor PT-2385 on a neurological disorder induced by deficiency of Irp2 Shen Jiaqi 1 Xu Li 1 Li Yuxuan 1 Dong Weichen 2 Cai Jing 3 Liu Yutong 1 Zhao Hongting 1 Xu Tianze 3 Holtz Esther Meyron 4 Chang Yanzhong 5 Qiao Tong 3 * Li Kuanyu 1 * 1Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China 2Department of Neurology, The Affiliated Jinling Hospital of Nanjing University Medical School, Nanjing, China 3Department of Vascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 4The Laboratory of Molecular Nutrition, Faculty of Biotechnology and Food Engineering, Technion – Israel Institute of Technology, Haifa, Israel 5College of Life Science, Hebei Normal University, Shijiazhuang, China

Edited and reviewed by: David Lynch, University of Pennsylvania, United States

 *Correspondence: Kuanyu Li likuanyu@nju.deu.cn Tong Qiao tongqiao@nju.edu.cn 29 08 2025 2025 19 1667076 16 07 2025 07 08 2025 Copyright © 2025 Shen, Xu, Li, Dong, Cai, Liu, Zhao, Xu, Holtz, Chang, Qiao and Li. 2025 Shen, Xu, Li, Dong, Cai, Liu, Zhao, Xu, Holtz, Chang, Qiao and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Protective effects of Hif2 inhibitor PT-2385 on a neurological disorder induced by deficiency of Irp2 by Shen, J., Xu, L., Li, Y., Dong, W., Cai, J., Liu, Y., Zhao, H., Xu, T., Holtz, E. M., Chang, Y., Qiao, T., and Li, K. (2021). Front. Neurosci. 15:715222. doi: 10.3389/fnins.2021.715222 iron regulatory protein 2 hypoxia inducible factor 2α glycolysis oxidative phosphorylation iron sulfur cluster neurodegeneration section-at-acceptance Neurodegeneration

There was a mistake in Figure 3 as published. One image was wrongly used in Figure 3B (left middle one), which is the same as in Figure 3C (right middle one). The corrected Figure 3 appears below.

The histological morphology and mitochondrial ultrastructure in the spinal cord and cerebellum of Irp2−/− mice are improved after PT-2385 administration. (A) The hematoxylin–eosin (H&E)-stained sections of the cerebellum of WT DMSO, Irp2−/− DMSO, and Irp2−/− PT-2385 mice. The dotted lines indicate Purkinje cell layers (top), and the arrows point to Purkinje cells (middle). The Purkinje cells framed by the dotted line are magnified four times (bottom). The scale bars are 160, 80, and 20 μm, respectively. (B, C) Transmission electron micrographs of the cerebellum (B) and spinal cord (C) of WT DMSO, Irp2−/− DMSO, and Irp2−/− PT-2385 mice. The scale bars are 1, 2.5, and 5 μm, respectively. The bottom panels are magnified images of myelin sheath and axonal degeneration. (D) The quantification of a normal mitochondria (relative ratio comparing with that in WT). Values represented the mean ± SD, n = 3. The ANOVA was used for statistics to evaluate the group differences. *P < 0.05, ****P < 0.0001, Irp2−/− DMSO vs. WT DMSO; #P < 0.05, ##P < 0.01, Irp2−/− PT-2385 vs. Irp2−/− DMSO.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.